Exploring mechanisms of psychedelic action using neuroimaging
This review (2024) discusses the pivotal role of neuroimaging in modern psychedelic research, providing insights into the acute and longer-term therapeutic effects of these substances. Evidence from fMRI, PET, and MEG/EEG studies informs computational models, offering a comprehensive understanding of the effects of psychedelics on human consciousness as well as supporting the advancement of psychedelic therapies.
Authors
- Robin Carhart-Harris
- David Nutt
- Christopher Timmermann
Published
Abstract
Modern psychedelic research and clinical development is at a crucial inflection point, with great potential for the treatment of many mental illnesses demonstrated but significant questions that remain unresolved. Neuroimaging has been pivotal in the modern era of psychedelic research, providing crucial insights into the acute effects of these drugs that revealed translational, clinical potential. Here we review this evidence from functional magnetic resonance imaging, positron emission tomography and magnetoencephalography/electroencephalography studies and describe how these findings inform computational models of both the acute action of psychedelics and their longer-term therapeutic effects. This approach, based on multi-modal neuroimaging, provides a solid evidence base for these therapies as they move forwards, as well as a fuller understanding of the powerful effects of psychedelics on the phenomenology of human consciousness.
Research Summary of 'Exploring mechanisms of psychedelic action using neuroimaging'
Introduction
Modern psychedelic research is at an inflection point: clinical studies show substantial therapeutic potential across several non-psychotic mental-health conditions, yet many mechanistic questions remain unresolved. Earlier work established 5-HT2A receptor agonism as the principal pharmacology of classic serotonergic psychedelics (psilocybin, LSD, DMT), and more recently compounds such as ketamine and MDMA have advanced clinically, but a detailed, mechanistic account linking acute drug action to longer-term therapeutic effects is still being developed. Erritzoe and colleagues set out to synthesise neuroimaging evidence from functional magnetic resonance imaging (fMRI), positron emission tomography (PET) and magnetoencephalography/electroencephalography (MEG/EEG) studies, and to show how these multi-modal data inform computational models of both acute psychedelic effects and enduring clinical outcomes. The review emphasises translational relevance: using imaging-derived molecular, functional and dynamical measures to build mechanistic bridges between receptor action, large-scale brain dynamics and therapeutic change.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Topics
- Authors
- APA Citation
Erritzoe, D., Timmermann, C., Godfrey, K., Castro-Rodrigues, P., Peill, J., Carhart-Harris, R. L., Nutt, D. J., & Wall, M. B. (2024). Exploring mechanisms of psychedelic action using neuroimaging. Nature Mental Health, 2(2), 141-153. https://doi.org/10.1038/s44220-023-00172-3
References (70)
Papers cited by this study that are also in Blossom
Knight, G., Rucker, J., Cleare, A. J. et al. · Frontiers in Psychiatry (2022)
Holze, F., Gasser, P., Müller, F. et al. · Biological Psychiatry (2023)
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)
Sessa, B. · British Journal of Psychiatry (2018)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Show all 70 referencesShow fewer
Carhart-Harris, R. L., Leech, R., Williams, T. M. et al. · British Journal of Psychiatry (2018)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T. et al. · Translational Psychiatry (2021)
Müller, F., Dolder, P. C., Schmidt, A. et al. · NeuroImage (2018)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Holze, F., Dolder, P. C., Ley, L. et al. · Neuropsychopharmacology (2020)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Girn, M., Rosas, F. E., Daws, R. E. et al. · Trends in Cognitive Sciences (2023)
Lord, L. D., Expert, P., Atasoy, S. et al. · NeuroImage (2019)
Atasoy, S., Vohryzek, J., Deco, G. et al. · Progress in Brain Research (2018)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Luppi, A. I., Carhart-Harris, R. L., Roseman, L. et al. · NeuroImage (2021)
Viol, A., Palhano-Fontes, F., Onias, H. et al. · Scientific Reports (2017)
Kaelen, M., Lorenz, R., Barrett, F. S. et al. · Biorxiv (2017)
Kaelen, M., Roseman, L., Kahan, J. et al. · European Neuropsychopharmacology (2016)
Preller, K. H., Pokorny, D., Hock, A. et al. · PNAS (2016)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Carhart-Harris, R. L., Wall, M. B., Erritzoe, D. et al. · International Journal of Neuropsychopharmacology (2013)
Daws, R. E., Timmermann, C., Giribaldi, B. et al. · Nature Medicine (2022)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)
Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)
Wall, M. B., Lam, C., Ertl, N. et al. · Journal of Affective Disorders (2023)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Pasquini, L., Palhano-Fontes, F., Araújo, D. B. · Journal of Psychopharmacology (2020)
Perry, C. M., Malina, M. · Psychopharmacology (2021)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)
Timmermann, C., Roseman, L., Schartner, M. et al. · Scientific Reports (2019)
Kometer, M., Pokorny, T., Seifritz, E. et al. · Psychopharmacology (2015)
Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)
Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Timmermann, C., Spriggs, M. J., Kaelen, M. et al. · Neuropharmacology (2018)
Alonso, J. N., Romero, S., Mañanas, M. A. et al. · International Journal of Neuropsychopharmacology (2015)
Schartner, M., Carhart-Harris, R. L., Barrett, A. B. et al. · Scientific Reports (2017)
Scott, G., Carhart-Harris, R. L. · Neuroscience of Consciousness (2019)
Timmermann, C., Vollenweider, F. X. · Trends in Cognitive Sciences (2023)
Bravermanová, A., Viktorinová, M., Tylš, F. et al. · Psychopharmacology (2018)
Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)
Kometer, M., Cahn, B. R., Andel, D. et al. · Biological Psychiatry (2011)
Deco, G., Cruzat, J., Cabral, J. et al. · Current Biology (2018)
Lawn, T., Dipasquale, O., Vamvakas, A. et al. · Psychopharmacology (2022)
Singleton, S. P., Luppi, A. I., Carhart-Harris, R. L. et al. · Nature Communications (2022)
Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E. et al. · Neuropharmacology (2023)
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Erritzoe, D., Smith, J. M., Fisher, P. M. et al. · Journal of Psychopharmacology (2019)
Timmermann, C., Kettner, H., Letheby, C. et al. · Scientific Reports (2021)
Nayak, S., Singh, M., Yaden, D. B. et al. · Journal of Psychopharmacology (2022)
Wall, M. B., Harding, R., Zafar, R. et al. · Molecular Psychiatry (2023)
Sarparast, A., Thomas, K., Malcolm, B. et al. · Psychopharmacology (2022)
Gukasyan, N., Nayak, S. · Preprints (2020)
Murphy, R., Murphy-Beiner, A., Kettner, H. et al. · Frontiers in Pharmacology (2022)
Cited By (7)
Papers in Blossom that reference this study
Agnorelli, C., Peill, J., Sawicka, G. et al. · Journal of Cerebral Blood Flow and Metabolism (2026)
Garcia-Romeu, A., Naudé, G. P., Rebman, A. W. et al. · Scientific Reports (2026)
Pellegrini, L., Fineberg, N. A., O'Connor, S. et al. · Comprehensive Psychiatry (2025)
Vohryzek, J., Luppi, A. I., Atasoy, S. et al. · Neuropsychopharmacology (2025)
Blackburne, G., Mcalpine, R. G., Fabus, M. et al. · Cell Reports (2025)
Timmermann, C., Sanders, J. W., Reydellet, D. et al. · Neuroscience of Consciousness (2025)
Godfrey, K., Weiss, B., Zhang, X. et al. · Neuroscience Applied (2025)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.